138
Participants
Start Date
October 22, 2022
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
Atezolizumab plus bevacizumab
Atezolizumab plus bevacizumab q3w
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Seoul National University Hospital
OTHER
Hanyang University
OTHER
Soon Chun Hyang University
OTHER
Asan Medical Center
OTHER